Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock
Sacubitril/valsartan is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for heart failure. We present a case of a patient with NYHA class IV systolic heart failure who was refractory to all other classes of heart failure medications and was...
Saved in:
| Main Authors: | H. A. Rawal, A. G. Kocheril |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2018/8231576 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Invasive Hemodynamic Monitoring in Acute Heart Failure and Cardiogenic Shock
by: Luca Baldetti, et al.
Published: (2025-06-01) -
The golden ratio in the pulmonary circulation in patients with heart failure and cardiogenic shock
by: Hoong Sern Lim, et al.
Published: (2025-04-01) -
Heart failure decompensation with cardiogenic shock exhibits distinct sequential inflammatory profiles
by: Darshan H. Brahmbhatt, et al.
Published: (2025-06-01) -
Treatment of heart failure related cardiogenic shock: Time to fill the evidence gap
by: Janine Pöss, et al.
Published: (2025-08-01) -
Outcome differences in acute vs. acute on chronic heart failure and cardiogenic shock
by: Tara L. Jones, et al.
Published: (2020-06-01)